A First Time in Human, Single Blind, Randomized, Placebo-controlled,Dose Escalating Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Parameters of Single Doses of GSK2330672 in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 12 Apr 2017
At a glance
- Drugs GSK 2330672 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 25 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
- 13 Oct 2011 Actual end date (October 2011) added as reported by ClinicalTrials.gov.
- 13 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History